Rational Pharmacotherapy in Cardiology

Advanced search

Felodipine in Treatment of Arterial Hypertension and Ischemic Heart Disease

Full Text:


Cardiovascular diseases are the leading cause of death both in the world and in the Russian Federation. The most significant contributors to the increase in mortality are arterial hypertension (AH) and ischemic heart disease (IHD). Dihydropyridine calcium channel blockers (CCBs) are the first line of treatment for these conditions. This is noted in the clinical guidelines for the diagnosis and treatment of AH and in the guidelines for the management of patients with chronic coronary syndromes. CCBs are a heterogeneous group of drugs that have both general and individual pharmacokinetic and pharmacodynamic properties. They are used in patients with AH and/or IHD, including those with concomitant diseases (diabetes mellitus, chronic kidney disease, bronchial asthma, chronic obstructive pulmonary disease, peripheral arterial disease). Felodipine is one of the CCBs. It has a combination of clinical effects, allowing the drug to be prescribed as a first-line therapy for AH, IHD and a combination of these diseases. This is noted in the registered indications for its use. This CCB has a sufficient evidence base of clinical trials demonstrating not only good antihypertensive and antianginal potential of the drug, but also the nephroprotection and cerebroprotection properties. The nephroprotective effect of felodipine is associated with a slowdown in the progression of chronic kidney disease, and the cerebroprotective effect is associated with a decrease in the risk of stroke and an improvement in cognitive functioning. The safety profile of felodipine is favorable: peripheral edema develops much less frequently. This is confirmed by the results of comparative studies. Felodipine is recommended for a wide range of patients with AH, IHD and their combination due to such clinical and pharmacological properties.

About the Authors

O. D. Ostroumova
Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Olga D. Ostroumova – MD, PhD, Professor, Head of Chair of Therapy and Polymorbid Pathology, Russian Medical Academy of Continuous Professional Education; Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Sechenov University

Barrikadnaya ul. 2/1, Moscow, 125993, 

Trubetskaya ul. 8-2, Moscow, 119991

I. A. Alautdinova
Russian Medical Academy of Continuous Professional Education
Russian Federation

Irina A. Alautdinova – MD, PhD, Assistant, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993

A. I. Kochetkov
Russian Medical Academy of Continuous Professional Education
Russian Federation

Alexey I. Kochetkov – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993

S. N. Litvinova
Russian Medical Academy of Continuous Professional Education
Russian Federation

Svetlana N. Litvinova – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993


1. Surinov A.E., Baranov E.F., Bezborodova T.S., et al., eds. Russian Statistical Yearbook 2018. Statistical Book. Moscow: Rosstat; 2018 (In Russ.)

2. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.

3. Lewington S., Clarke R., Qizilbash N., et al; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. DOI:10.1016/s0140-6736(02)11911-8.

4. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-98. DOI:10.1056/NEJMsa053935.

5. World Health Organization. Cardiovascular disease [cited by July 04, 2020]. Available from:

6. Boytsov S.A., Balanova Y.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-2014-4-4-14.

7. Arterial hypertension in adults. Clinical guidelines [cited by Jul 04, 2020]. Available from:!/recomend/687 (In Russ.)

8. Julius S., Palatini P., Kjeldsen S.E., et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109(5):685-92. DOI:10.1016/j.amjcard.2011.10.025.

9. Clark C.E., Taylor R.S., Shore A.C., et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379(9819):905-14. DOI:10.1016/S0140-6736(11)61710-8.

10. Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. DOI:10.1016/S0140-6736(15)01225-8.

11. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.

12. Brunström M, Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178(1):28-36. DOI:10.1001/jamainternmed.2017.6015.

13. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens. 2015;33(7):1321-41. DOI:10.1097/HJH.0000000000000614.

14. Rutten F.H., Zuithoff N.P., Hak E., et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880-7. DOI:10.1001/archinternmed.2010.112.

15. Ostroumova O.D., Vikentev V.V., Abrosimov A.G., Smoliarchuk E.A. Dihydropyridine calcium antagonists: conscious choice. Systemic Hypertension. 2017;14(1):61-68. (In Russ.)

16. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751-6. DOI:10.1016/s0140-6736(99)10327-1.

17. Kukes V.G., ed. Clinical Pharmacology: Textbook. M.: GEOTAR-Media; 2006 (In Russ.) [Кукес В.Г., ред. Клиническая фармакология: Учебник. М.: ГЭОТАР-Медиа; 2006].

18. Schaefer R.M., Aldons P.M., Burgess E.D., et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract. 1998;52(6):381-6.

19. Glezer M.G., Novikova M.V., Prourzina N.L., Saygitov R.T. Comparative assessment of the effect of calcium antagonist therapy with felodipine and amlodipine on the water sectors balance of the body of a woman with arterial hypertension. Problemy Zhenskogo Zdorov'ya. 2009;1(4):24-8 (In Russ.)

20. Jamerson K., Weber M.A., Bakris G.L., et al. for the Accomplish trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. DOI:10.1056/NEJMoa0806182.

21. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.

22. Liebson P.R., Grandits G.A., Dianzumba S., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91(3):698-706. DOI:10.1161/01.cir.91.3.698.

23. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62. DOI:10.1016/s0140-6736(98)04311-6.

24. Liu L., Zhang Y., Liu G., et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157-72. DOI:10.1097/

25. Ekbom T., Linjer E., Hedner T., et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press. 2004;13(3):137-41. DOI:10.1080/08037050410014944.

26. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract. 2008;62(1):97-108. DOI:10.1111/j.1742-1241.2007.01620.x.

27. Herlitz H., Harris K., Risler T., et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant. 2001;16(11):2158-65. DOI:10.1093/ndt/16.11.2158.

28. Dietz J.D., Du S., Bolten C.W., et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008;51(3):742-8. DOI:10.1161/HYPERTENSIONAHA.107.103580.

29. Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Calcium antagonists: current aspects of application in cardiology. Consilium Medicum. 2006;8(11):113-7 (In Russ.)

30. Iadecola C., Yaffe K., Biller J., et al; American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):e67-e94. DOI: 10.1161/HYP.0000000000000053.

31. Gąsecki D., Kwarciany M., Nyka W., Narkiewicz K. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547-58. DOI:10.1007/s11906-013-0398-4.

32. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561-6. DOI:10.1056/NEJM199005313222203.

33. Launer L.J., Masaki K., Petrovitch H., et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846-51.

34. Köhler S., Baars M.A., Spauwen P., et al. Temporal evolution of cognitive changes in incident hypertension: prospective cohort study across the adult age span. Hypertension. 2014;63(2):245-51. DOI:10.1161/HYPERTENSIONAHA.113.02096.

35. Tzourio C., Dufouil C., Ducimetière P., Alpérovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology. 1999;53(9):1948-52. DOI:10.1212/wnl.53.9.1948.

36. Hajjar I., Catoe H., Sixta S., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci. 2005;60(1):67-73. DOI:10.1093/gerona/60.1.67.

37. Levi Marpillat N., Macquin-Mavier I., Tropeano A.I., et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073-82. DOI:10.1097/HJH.0b013e3283603f53.

38. Hernandorena I., Duron E., Vidal J.S., Hanon O. Treatment options and considerations for hypertensive patients to prevent dementia. Expert Opin Pharmacother. 2017;18(10):989-1000. DOI:10.1080/14656566.2017.1333599.

39. Lehrl S., Grässel E., Eicke C. Wirkung von Felodipin bei hypertonen Patienten mit leichten Hirnleistungsstörungen in einer randomisierten Doppelblindstudie. Dtsch Med Wochenschr. 2000;125(45):1350-5. DOI:10.1055/s-2000-8179.

40. Rothwell P.M., Howard S.C., Dolan E., et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469- 80. DOI:10.1016/S1474-4422(10)70066-1.

41. Pepine C.J., Handberg-Thurmond E., Marks R.G., et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32(5):1228-37. DOI:10.1016/s0735-1097(98)00423-9.

42. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805- 16. DOI:10.1001/jama.290.21.2805.

43. Stable ischemic heart disease. Clinical guidelines (2016). [cited by Jul 04, 2020]. Available from:!/recomend/133 (In Russ.)

44. Thadani U. Management of Stable Angina - Current Guidelines: A Critical Appraisal. Cardiovasc Drugs Ther. 2016;30(4):419-426. DOI:10.1007/s10557-016-6681-2.

45. Rousan T.A., Mathew S.T., Thadani U. Drug Therapy for Stable Angina Pectoris. Drugs. 2017;77(3):265-84. DOI:10.1007/s40265-017-0691-7.

46. Belsey J., Savelieva I.., Mugelli A, Camm A.J. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(7):837-48. DOI:10.1177/2047487314533217.

47. Pharmacological group - Calcium channel blockers. Register of Medicines of Russia [cited by Jul 04, 2020]. Available from: (In Russ.)

48. Ulbasheva E.A., Namitokov A.M., Kandinsky M.V., Kosmacheva E.D. Clinical patterns of vasospastic angina. Complex Issues of Cardiovascular Diseases. 2018;7(4):121-7 (In Russ.) DOI: 10.17802/2306-1278-2018-7-4-121-127.

49. Metcalfe M.J., Chan-Wah-Hak N.S., Jennings K. The effects of treatment with felodipine as a single agent in coronary artery disease. Br Heart J. 1989;61(3):258-61. DOI:10.1136/hrt.61.3.258.

50. Sheridan J.V., Thomas P., Routledge P.A., Sheridan D.J. Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris. Br J Clin Pharmacol. 1987;23(4):391-6. DOI:10.1111/j.1365-2125.1987.tb03067.x.

51. Emanuelsson H., Holmberg S. No adverse effects from high doses of felodipine to patients with coronary heart disease. Clin Cardiol. 1985;8(6):329-36. DOI:10.1002/clc.4960080605.

52. Dunselman P., Liem A.H., Verdel G., et al. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN). Eur Heart J. 1997;18(11):1755-64. DOI:10.1093/oxfordjournals.eurheartj.a015170.

53. Belsey J., Savelieva I., Mugelli A., Camm A.J. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(7):837-48. DOI:10.1177/2047487314533217.

54. Kotovskaya Yu.V., Bagmanova N.Kh., Milto A.S., et al. Efficiency and tolerance of antihypertensive therapy based on felodipine in patients with arterial hypertension in a hospital setting. Kardiologiia. 2004;44 (3):47-51 (In Russ.)


For citations:

Ostroumova O.D., Alautdinova I.A., Kochetkov A.I., Litvinova S.N. Felodipine in Treatment of Arterial Hypertension and Ischemic Heart Disease. Rational Pharmacotherapy in Cardiology. 2020;16(4):654-662. (In Russ.)

Views: 879

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)